Mortality Studies
Understanding mortality patterns in ME/CFS is essential for both clinical practice and actuarial assessment (life insurance underwriting). While early concerns suggested potentially elevated mortality, large population-based cohort studies have provided more nuanced evidence. This section synthesizes findings from registry studies, clinical cohorts, and memorial record analyses.
1 All-Cause Mortality: Evidence from Population Cohorts
1.1 Large Registry-Based Studies
The most rigorous evidence comes from population-based registry studies with appropriate comparison groups: Roberts et al. (2016) – England and Wales National Registry. This landmark study published in The Lancet (Roberts et al. 2016) analyzed mortality in 2,147 ME/CFS patients identified through English and Welsh general practice registries, with 7-year follow-up (2007–2013). The study recorded 17 deaths during follow-up. Key findings:
All-cause mortality SMR: 1.14 (95% CI: 0.65–1.85, \(p = 0.67\))
No statistically significant elevation in all-cause mortality
Cancer-specific SMR: 1.39 (95% CI: 0.60–2.73, \(p = 0.45\)) – not significant
Suicide-specific SMR: 6.85 (95% CI: 2.22–15.98, \(p = 0.002\)) – highly significant Notably, 5 of the 17 deaths were suicides, and 60% of suicide victims had no documented depression diagnosis. The authors interpreted this as suggesting that ME/CFS-specific factors (functional limitation, hopelessness about prognosis, dismissive medical encounters) may contribute to suicide risk independent of comorbid psychiatric conditions, though the small sample size (n=5 suicides) limits the strength of this inference. Smith et al. (2006) – US Multi-Center Cohort. A US study (Smith, Noonan, and Buchwald 2006) followed 1,201 patients with chronic fatigue for up to 14 years, using National Death Index (NDI) linkage for mortality ascertainment. Key findings:
All-cause mortality: No elevation above expected rates for age and sex
Suicide rate: \(>\) 8 times higher than US general population
SMR for suicide particularly elevated in “chronic fatigue” not meeting full CFS criteria (SMR: 14.2) compared to CFS (SMR: 3.6)
The authors noted that the higher suicide rate in chronic fatigue (vs. CFS) patients may reflect the additional burden of lacking a recognized diagnosis
1.2 Conflicting Evidence: Memorial Record Studies
Studies based on memorial records and caregiver surveys have reported more concerning findings, but these suffer from significant selection bias toward severely ill and deceased patients: McManimen et al. (2016) – Caregiver Survey. Analysis of 56 deaths reported by caregivers (Sarah L. McManimen et al. 2016) found:
- Mean age at death: 55.9 years vs. 73.5 years in general population (\(p < 0.0001\))
- 48.2% of deceased were bedridden before death
- Mean age at cardiovascular death: 58.8 years vs. 77.7 years (\(p < 0.0001\)) Critical limitation: Memorial records inherently overrepresent severe cases and premature deaths (survivors do not appear in memorials). This creates profound selection bias.
| Measure | Finding |
|---|---|
| Study | Sirotiak, Amro (2025) (Sirotiak and Jason 2025) — Updated Memorial Analysis |
| Sample | 505 deaths |
| Mean age at death | 52.5 years (SD = 16.7) |
| Most frequent causes | ME/CFS complications (28.3%), suicide (25.4%), cancer (23.0%), cardiovascular disease (14.2%) |
While concerning, these findings must be interpreted cautiously given selection bias. The authors acknowledge that memorial records may capture “the tip of the iceberg” of severe, fatal cases rather than representing typical ME/CFS mortality patterns.
2 Cause-Specific Mortality
2.1 Suicide: The Most Robust Finding
Across all study types—registry cohorts, clinical cohorts, and memorial records—suicide mortality is consistently and substantially elevated:
| Study | SMR or Rate Ratio | Significance |
|---|---|---|
| Roberts et al. (2016) | 6.85 | \(p = 0.002\) |
| Smith et al. (2006) – CFS | 3.6 | Significant |
| Smith et al. (2006) – Chronic Fatigue | 14.2 | Highly significant |
| Jason et al. (2006) | 2nd most common cause | — |
Suicidal Ideation Prevalence. Cross-sectional surveys reveal alarming rates of suicidal thoughts:
39–57% of moderately to severely ill ME/CFS patients report suicidal ideation (Chu et al. 2021)
Compare to 4% in general US population
7.1% have suicidal ideation without clinical depression (Brown and Jason 2020) Risk Factors for Suicide in ME/CFS. Research has identified ME/CFS-specific suicide risk factors distinct from typical psychiatric risk factors (Brown and Jason 2020):
Severe functional limitations (strongest predictor)
Use of “CFS” diagnostic label (associated with stigma — experimentally confirmed: CFS label generates more negative attributions than alternative names (Jason et al. 2002)) – 2.81\(\\times\) increased risk
Absence of comorbidities (paradoxically increases risk, possibly due to lack of medical legitimacy) – 3.48\(\\times\) increased risk
Lack of social support and financial resources
Hopelessness about prognosis and treatment availability
Stigma and gaslighting from healthcare providers, which independently predicts suicidal ideation after controlling for depression (Stephanie L. McManimen et al. 2018) (Johnson et al. 2022) Notably, 60% of ME/CFS patients who died by suicide in the Roberts cohort had no documented depression diagnosis, suggesting that ME/CFS-specific suffering—not psychiatric comorbidity—drives suicide risk.
2.2 Cardiovascular Mortality: Conflicting Evidence
Concerning Signals from Memorial Records. Memorial record studies suggest elevated cardiovascular mortality:
Mean age at cardiovascular death: 58.8 years vs. 77.7 years (Sarah L. McManimen et al. 2016)
Cardiovascular disease: 14.2% of deaths in recent memorial analysis (Sirotiak and Jason 2025)
Heart failure identified as most common cause of death in Jason et al. (2006) (Jason et al. 2006) Cardiovascular Disease Prevalence. Epidemiological surveys suggest elevated cardiovascular disease prevalence in ME/CFS:
Approximately 25% of ME/CFS patients report history of heart disease or hypertension vs. approximately 5% in the general population (Komaroff and Buchwald 1991)
A systematic review and meta-analysis estimated 51.4% prevalence of any cardiac abnormalities Campen and Visser (2019)
Analysis of 2021–2022 NHIS data reported aOR 3.26 (95% CI: 2.85–3.72, \(p < 0.001\)) for cardiovascular disease after adjusting for traditional risk factors (Denu et al. 2025) Mechanism Uncertainty. Critically, cardiovascular dysfunction in ME/CFS does not appear to follow typical atherosclerotic pathways. Instead, it is characterized by:
Reduced stroke volume and cardiac output
Impaired cerebral blood flow
Small heart size (“athlete’s heart” in reverse)
These abnormalities are not influenced by deconditioning Implication: Standard cardiovascular risk models developed for atherosclerotic disease may not apply to ME/CFS. Whether this translates to elevated mortality risk remains unclear, and large registry studies have not confirmed elevated cardiovascular mortality.
2.3 Cancer Mortality: No Evidence of Elevation
Despite cancer appearing in memorial records (23.0% of deaths (Sirotiak and Jason 2025)), population-based studies find no significant elevation:
- Roberts et al.: Cancer-specific SMR 1.39 (95% CI: 0.60–2.73, \(p = 0.45\)) (Roberts et al. 2016)
- Age at cancer death in memorial records not significantly different from general population
3 Actuarial and Insurance Industry Perspective
3.1 Mortality Risk Assessment
The insurance industry has begun evaluating ME/CFS mortality risk. Gen Re, a major global reinsurer, published an analysis in 2023 (GenRe 2023) concluding: > > “There seems to be no significant difference between all-cause mortality rates of ME/CFS patients and the general population.” However, the report notes that patients with “very severe fatigue” may have elevated cardiovascular mortality, though evidence remains limited.
3.2 Disability vs. Mortality: The Primary Actuarial Concern
Critically, disability—not mortality—represents the primary actuarial risk in ME/CFS:
- Recovery rates: \(<\) 10%
- Unemployment: 35–69%
- Annual US economic costs: $17–24 billion
- Functional impairment drives actuarial risk more than mortality This distinction matters: life insurance underwriters assess mortality risk, while disability insurers assess functional capacity. ME/CFS poses greater risk to the latter.
4 Methodological Challenges and Evidence Quality
4.1 Why Study Results Differ
The stark discrepancy between registry studies (no elevated all-cause mortality) and memorial records (mean age at death 52–56 years) reflects methodological differences:
- Selection bias: Memorial records capture only deaths, inherently overrepresenting severe and fatal cases. Registry studies capture all diagnosed patients regardless of outcome.
- Case definition: Broader “chronic fatigue” definitions (Smith et al.) vs. strict ME/CFS criteria (Roberts et al.) vs. patient-identified cases (memorial records) represent different populations.
- Cohort source: Clinical cohorts (treatment-seeking patients) vs. population-based registries (all diagnosed patients) vs. memorial nominations (deceased patients) have fundamentally different selection mechanisms.
- Follow-up duration: Longer studies (Smith: 14 years) may capture delayed mortality effects better than shorter studies (Roberts: 7 years).
4.2 Highest-Quality Evidence
The most methodologically rigorous studies are:
- Roberts et al. (2016): \(n = 2{,}147\), 7-year follow-up, registry-based, appropriate comparison group (Roberts et al. 2016)
- Smith et al. (2006): \(n = 1{,}201\), up to 14-year follow-up, clinic-based with NDI linkage (Smith, Noonan, and Buchwald 2006) Both studies found no elevation in all-cause mortality but substantial elevation in suicide mortality.
5 Summary: Evidence-Based Conclusions
- All-cause mortality: No consistent evidence of elevation in large, well-designed cohort studies with appropriate comparison groups. Memorial record studies showing early death are subject to severe selection bias.
- Suicide mortality: Consistently and substantially elevated (6–8\(\\times\) general population) across all study types. This represents a legitimate and well-documented mortality risk.
- Cardiovascular mortality: Conflicting evidence. Memorial records suggest elevation, but mechanism differs from atherosclerotic disease and large registry studies have not confirmed excess mortality. Requires further research.
- Cancer mortality: No evidence of elevation in population-based studies.
- Life expectancy: Cannot be reliably estimated due to methodological limitations. Best available evidence suggests normal life expectancy for all-cause mortality, with elevated suicide risk as the primary exception.
- Actuarial implications: Disability represents greater actuarial risk than mortality in ME/CFS. Life insurance underwriters may focus on suicide risk (well-documented) but have weak evidence for blanket mortality risk assessment. The robust evidence of elevated suicide mortality—particularly among patients without comorbid depression—highlights suicide prevention as a critical clinical priority in ME/CFS care. Risk factors include severe functional limitation, lack of social support, medical dismissal, and hopelessness about prognosis. Clinical interventions should address ME/CFS-specific suffering (energy limitations, loss of identity and purpose, medical gaslighting) rather than treating suicide risk as a purely psychiatric issue.